Tuesday, November 22, 2011

Reprogramming Urokinase into an Antibody-Recruiting Anticancer Agent

The authors of this paper used chemical inducers of dimerization to target immune cells to cancer cells. One end of the small molecule targets urokinase-type plasminiogen activator receptor (uPAR), which is overexpressed at the surface of many cancer cells. The other end of the small molecule targets an antibody which recruits immune effector cells. Both phagocytosis and cytotoxicity of cancer cells were able to be triggered with this system. This technology could be very useful in the treatment of cancer.

No comments:

Post a Comment